Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd conducts its operations across a diverse range of business sectors. Its core activities encompass pharmaceutical research and development, clinical studies, and the field of biomedicine, alongside investments in commercial properties and various other ventures. This enterprise, officially renamed Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021, previously operated as Xinjiang Baihuacun Co., Ltd. Established in 1959, the company maintains its headquarters in Urumqi, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,